Patent Focus
Journal of Generic Medicines (2007) 5, 85–90. doi:10.1057/palgrave.jgm.4950092; published online 7 August 2007
Fluvastatin and Atorvastatin: A comparison of patent protection (Part 2)
Researched and written by Genericsweb
Genericsweb is a provider of information products and services to the generic pharmaceutical industry. Its flagship product, Pipeline Patent Intelligence is the industry leader in providing comprehensive research and analysis of patents protecting pharmaceutical products worldwide.
No part of this section may be reproduced, stored in a retrieval system or transmitted in any form by any means without the prior permission of Genericsweb Pty Ltd. The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations delivered in this report are based on information gathered in good faith from both primary and secondary sources, whose accuracy has not been verified. As such, Genericsweb can accept no liability whatsoever for actions taken based on any information contained herein.
For further information please contact:
Leighton Howard
Genericsweb Pty Ltd
PO Box 202
Balmain 2041
Australia
Email: l.howard@genericsweb.com
Genericsweb maintains its headquarters in Sydney, Australia and has a regional office in the UK.
Leighton Howard1
1is a patent information expert with extensive generics experience. He has worked within the professional patent information industry and major generic pharmaceutical firms and now provides consultancy services to the generics industry and government organisations via his company XIP Pty Ltd. He is also the founder of Genericsweb and remains instrumental in maintaining the high quality and accuracy of data contained in Pipeline Patent Intelligence.
